Pharma Privat GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe. Founded in 2005, the company has established itself as a leader in the development and distribution of high-quality generic medications and innovative healthcare solutions. With a focus on prescription drugs, over-the-counter products, and specialised therapies, Pharma Privat GmbH is committed to enhancing patient care through its unique offerings. The company’s dedication to quality and compliance has earned it a strong market position, recognised for its reliability and efficiency in the supply chain. Notable achievements include strategic partnerships and a robust portfolio that caters to diverse therapeutic areas, ensuring that Pharma Privat GmbH remains at the forefront of the pharmaceutical landscape.
How does Pharma Privat GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharma Privat GmbH's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharma Privat GmbH, headquartered in Germany, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. Without available emissions data or reduction initiatives, it is unclear how Pharma Privat GmbH is addressing its carbon footprint or contributing to climate action within the pharmaceutical sector. The lack of transparency in emissions reporting and climate commitments may reflect broader industry challenges in sustainability practices.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharma Privat GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
